These new findings from BRAVE-AA trials show most adult and adolescent responders to baricitinib treatment achieved full scalp hair regrowth, with significant improvements seen as early as Week 8.

The POSITIVE study demonstrates that tildrakizumab provides sustained relief from psoriasis skin symptoms while enhancing psychological well-being and partner quality of life, highlighting its role as an important option in holistic management of psoriatic disease.

This study highlights key baseline risk factors, including BMI ≥30 and PEST score 2, that predict progression from psoriasis to PsA over 24 months. It explores the impact of biologic treatments on risk reduction, offering insights for dermatologists and rheumatologists.